Trends in Transcatheter Versus Surgical Aortic Valve Replacement Outcomes in Patients With Low-Surgical Risk: A Systematic Review and Meta-Analysis of Randomized Trials Publisher Pubmed



Kazemian S^{1, 2} ; Fallahtafti P^{2, 3} ; Sharifi M² ; Mohammadi NSH^{1, 2} ; Soleimani H^{1, 2} ; Moghadam AS² ; Karimi E^{2, 3} ; Sattar Y⁴ ; Jenab Y^{1, 2} ; Mehrani M^{1, 2} ; Hajizeinali A² ; Iskander M⁵ ; Sabet MF⁶ ; Salehi N⁷ Show All Authors Show Affiliations
Source: Journal of the American Heart Association Published:2024

Abstract

BACKGROUND: Limited data exist on long-term outcomes after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). This meta-analysis aims to elucidate outcome trends following TAVR versus SAVR in patients with severe aortic stenosis and low-surgical risk. METHODS AND RESULTS: A systematic search was conducted in PubMed, Embase, Scopus, and the Cochrane Library databases from inception until May 2024, to identify studies comparing TAVR versus SAVR in patients with low-surgical risk (Society of Thoracic Surgeons predicted risk of mortality score <4%). The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular mortality, stroke, disabling stroke, rehospitalization, myocardial infarction, aortic valve reintervention, permanent pacemaker implantation, and new-onset atrial fibrillation. Binary random-effects models were used to compare the risk of each outcome across various follow-up intervals and the risk of bias was assessed using the Cochrane Collaboration’s Risk of Bias-2 tool. The meta-analysis included 6 randomized trials including 4682 patients. TAVR was associated with a lower risk of all-cause mortality than SAVR in the 30-day (hazard ratio [HR: 0.45] [95% CI: 0.26–0.77], I2: 0%) and 30-day to 1-year (HR: 0.55 [95% CI: 0.37–0.81], I2: 16%) follow-ups. However, the risk of all-cause mortality was similar during >1-year follow-ups. TAVR was associated with a significantly lower risk of cardiovascular mortality, disabling stroke, rehospitalization, new-onset atrial fibrillation, and a higher risk of permanent pacemaker implantation compared with SAVR during the 30-day follow-up. CONCLUSIONS: TAVR was associated with a lower risk of all-cause mortality within the first year of post-procedural follow-up compared with SAVR. However, the risk of all-cause mortality was similar in >1-year follow-ups. © 2024 The Author(s).